All In Biotech

Drug Trial Radar · NCT07936266

Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

A Phase I Open-label, Multicenter Trial of Asciminib (ABL001) Added to Inotuzumab Ozogamicin (Besponsa®) in Patients With Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Mar 31, 2027

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Sunil G. IyerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.

Conditions

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • AsciminibDrug

    Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket), and is an approved TKI in newly-diagnosed and previously-treated chronic myeloid leukemia (CML). It is a non-chemotherapeutic, oral agent which specifically and potently targets the mutant Philadelphia chromosome driven by t(9;22). Due to its novel mechanism of action as a STAMP, asciminib is active in the setting of mutations in the BCR-ABL ATP-binding pocket including the T315I gatekeeper mutations, which confers resistance to first- and second-generation tyrosine kinase inhibitors (TKIs). Asciminib has not yet been studied in Philadelphia-chromosome positive B-ALL.

  • Inotuzumab ozogamicinDrug

    Inotuzumab ozogamicin (INO) is an antibody-drug conjugate which targets CD22, an antigen present in \>90% of B-ALL cases. INO is FDA approved and a standard-of-care treatment in relapsed/refractory B-ALL. The drug is approved and active in Ph-positive and -negative disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse eventsTime frame: 36 Months
  2. Maximum Tolerated Dose (MTD) of asciminibTime frame: 36 Months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida · Not yet recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Not yet recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • University of Washington Fred Hutchinson Comprehensive Cancer Center

    Seattle, Washington · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.